143 studies found for:    "psoriatic arthritis"
Show Display Options
Rank Status Study
21 Completed
Has Results
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: etanercept
22 Recruiting Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
23 Recruiting Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Placebo
24 Completed
Has Results
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
Condition: Psoriatic Arthritis
Intervention: Drug: Etanercept
25 Recruiting Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib 5 mg BID;   Drug: Tofacitinib 10 mg BID;   Drug: Adalimumab;   Drug: Placebo
26 Completed Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
Condition: Psoriatic Arthritis
Intervention:
27 Recruiting Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
28 Active, not recruiting
Has Results
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast;   Drug: Placebo
29 Completed A Placebo-Controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Alefacept;   Drug: Methotrexate;   Drug: Placebo
30 Recruiting Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: Open label H.P. Acthar Gel
31 Completed Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
Condition: Psoriatic Arthritis
Intervention:
32 Recruiting Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Secukinumab (AIN457);   Drug: Placebo
33 Completed Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Conditions: Psoriasis;   Psoriatic Arthritis
Intervention:
34 Recruiting Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib;   Other: Placebo
35 Active, not recruiting Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Interventions: Drug: Secukinumab (75 mg);   Drug: Secukinumab (150 mg);   Drug: Placebo Comparator
36 Withdrawn A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Conditions: Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis
Intervention: Drug: No intervention
37 Withdrawn Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
Condition: Psoriatic Arthritis
Intervention: Biological: adalimumab (Humira)
38 Active, not recruiting Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20mg Apremilast;   Drug: Placebo + 30mg Apremilast
39 Completed Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Intervention: Drug: adalimumab
40 Completed
Has Results
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
Conditions: Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years